The acute myeloid leukemia (AML) treatment landscape has changed substantially since 2017. New targeted drugs have emerged, including venetoclax to target B-cell lymphoma 2, midostaurin and gilteritinib to targe
Rydapt is used together with other cancer medicines to treat acute myeloid leukemia.Rydapt is also used to treat certain rare blood disorders, including systemic mastocytosis with mast cell leukemia or other cancers affecting the blood, bone marrow, or lymphatic tissue....
This is especially true for acute myeloid leukemia patients whose front-line treatment is generally a combination of an anthracyclin and the nucleoside analog Ara-C. Here, we show that a role of these drugs is the inhibition of the SUMO pathway. They induce a progressive loss of conjugation ...
Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kin...
Besponsa is an antineoplastic biological drug used to treat adults and children aged 1 year and older with a type of blood cancer called CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) (also known as acute lymphocytic leukemia)....
Acute myeloid leukemia (AML) is the second most common form of leukemia and the most frequent cause of leukemia-related deaths in the United States. The incidence of AML increases with advancing age and the prognosis for patients with AML worsens substan
Acute myeloid leukemia ANG: Angiopep-2 APL: Acute promyelocytic leukemia ATF: Amino-terminal fragment ATO: Arsenic trioxide ATRA: All-trans retinoic acid BBB: Blood–brain barrier BHD: Bai-Hu decoction BSA: Bovine serum albumin BSM: Basilicum seed mucilage ...
In June, HYML-122, a drug targeting acute myeloid leukemia, was approved by the SDA for a clinical trial. It was developed by a research team from Hefei Institute of Physical Science. If the trial is successful, the drug will be put into clinical use in five years. ...
Cytarabine-resistant PDX from acute myeloid leukemia (AML) patients exhibited increased mitochondrial mass, preserved functional mitochondria, elevated CD36 expression and increased OXPHOS status [47,48]. In AML cell lines resistant to Cytrabine and arsenic trioxide, OXPHOS was identified as a hallmark...
12, 72) has been successfully used to treat acute myeloid leukemia (AML), but it is not effective for other common types of AMLs89. Tranylcypromine (Fig. 12, 73) could also exert effects on AMLs by inducing the leukemic cells to mature and die naturally. Selective serotonin reuptake ...